1. Scrip
  2. >>R&D

RAINFALLs On Lilly's Cyramza Stomach Cancer Parade

 
• By Alexandra Shimmings

A lack of overall survival benefit in first-line stomach cancer in a Phase III trial has scuppered Eli Lilly's hopes of expanding Cyramza's use into a new and relatively empty market.

Raindrops
Rainy days for Lilly's Cyramza plans • Source: Shutterstock

Eli Lilly & Co.'s VEGF inhibitor Cyramza (ramucirumab) has failed to improve overall survival when used first line in stomach cancer, top-line data from the RAINFALL study show. The company has dropped plans to file for a supplemental approval in what could have been a lucrative expanded indication where there is limited competition.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

AstraZeneca COPD Drug Breztri Breezes Through Asthma Trials

 
• By Kevin Grogan

The triple therapy improves lung function in the Phase III KALOS and LOGOS studies

DIA Korea: Medical Turmoil, Global Factors Blunt Korea’s Trial Edge

 
• By Jung Won Shin

DIA Korea hears how multiple domestic and global factors are affecting the environment for clinical trials in South Korea, and what actions may be taken to address this.

Moderna Punts On US Vaccine Policy Changes, Will Focus More On Cancer

 
• By Joseph Haas

On its Q1 earnings call, Moderna avoided criticizing policy changes affecting vaccines but de-emphasized its flu/COVID-19 vaccine for under-50 and prioritized cancer programs.

GSK Talks Up Nucala COPD Hospitalization Data In Challenge To Dupixent

 
• By Kevin Grogan

As the PDUFA date for the UK major’s IL-5 inhibitor draws close.

More from R&D